文献速递甲状腺疾病

pT3期甲状腺乳头状癌的异质性预后及延迟风险分层的影响

Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification.
PubMed 文献 · Thyroid · 2017-04-24

本研究纳入560例在本机构治疗随访的pT3期甲状腺乳头状癌患者,分为三组:组1为pT3且肿瘤≤10 mm;组2为pT3且肿瘤>10 mm伴甲状腺外侵犯;组3为pT3因肿瘤大小>4 cm。10年无病生存率全队列为75%,组1、组2、组3分别为89%、67%、82%(p<0.0001)。多因素分析显示淋巴结受累、男性、组2与无病生存率降低显著相关。6-8个月检查正常时,组1-3的10年无病生存率分别升至98%、96%、91%。结论认为无淋巴结受累等不良预后因素时,≤10 mm伴甲状腺外侵犯和大肿瘤>4 cm无甲状腺外侵犯复发风险低;淋巴结受累尤其是侧颈区(N1b)是pT3期甲状腺乳头状癌复发的强预后因素;延迟风险分层可应用于pT3期甲状腺乳头状癌患者。

要点

  • pT3期甲状腺乳头状癌10年无病生存率全队列75%,组1、组2、组3分别为89%、67%、82%(p<0.0001)。
  • 多因素分析显示淋巴结受累、男性、组2与无病生存率降低显著相关。
  • 6-8个月检查正常时,组1-3的10年无病生存率分别升至98%、96%、91%,初始淋巴结受累似乎不再影响预后。

核心结论

  • 无淋巴结受累等不良预后因素时,≤10 mm伴甲状腺外侵犯和大肿瘤>4 cm无甲状腺外侵犯的pT3期甲状腺乳头状癌复发风险低。
  • 淋巴结受累尤其是侧颈区(N1b)是pT3期甲状腺乳头状癌复发的强预后因素。
  • 延迟风险分层可应用于pT3期甲状腺乳头状癌患者;首次检查即达治愈者(包括有限淋巴结受累者)结局极佳,应促使临床医生相应调整后续管理。

研究设计与样本

  • 研究纳入560例在本机构治疗和随访的pT3期甲状腺乳头状癌患者,分为三组:组1为pT3且肿瘤≤10 mm;组2为pT3且肿瘤>10 mm伴甲状腺外侵犯;组3为pT3因肿瘤大小>4 cm。
  • 采用Kaplan-Meier法估计无病生存率,并在各组中通过单因素和多因素Cox模型分析相关预后特征。
  • 按6-8个月时的状态(缓解与否)研究各组无病生存率。

主要发现

  • 10年无病生存率全队列为75%,组1、组2、组3分别为89%、67%、82%(p<0.0001)。
  • 多因素分析识别出三个与无病生存率降低显著相关的因素:淋巴结受累、男性、组2(>1 cm伴甲状腺外侵犯)。
  • pT3 N0/Nx且肿瘤>10 mm伴甲状腺外侵犯的患者与其他pT3 N0/Nx患者相比,呈现预后更差的趋势。
  • 6-8个月检查正常时,组1-3的10年无病生存率分别升至98%、96%、91%,且此时初始淋巴结受累似乎不再影响这些组的预后。

临床怎么用

  • 作者认为,无淋巴结受累等不良预后因素时,≤10 mm伴甲状腺外侵犯和大肿瘤>4 cm无甲状腺外侵犯的pT3期甲状腺乳头状癌复发风险低。
  • 作者认为,淋巴结受累尤其是侧颈区(N1b)是pT3期甲状腺乳头状癌复发的强预后因素。
  • 作者认为,延迟风险分层可应用于pT3期甲状腺乳头状癌患者;首次检查即达治愈者(包括有限淋巴结受累者)结局极佳,应促使临床医生相应调整后续管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Papillary thyroid carcinomas (PTC) in the pT3 category constitute a heterogeneous group of tumors with a variable risk of recurrence. The objectives of this study were (i) to estimate disease-free survival (DFS) and identify prognostic factors associated with recurrence in a cohort of pT3 PTC, and (ii) to evaluate the concept of delayed risk stratification in a cohort of pT3 tumors. METHODS: A total of 560 patients with pT3 PTC, treated and followed at the authors' institution, were studied. They were divided into three groups: group 1, pT3 ≤10 mm; group 2, pT3 >10 mm with extrathyroidal invasion (ETI); and group 3, pT3 due to a tumor size >4 cm. DFS was estimated using the Kaplan-Meier method, and associated prognostic features were studied in univariate and multivariate Cox model-based analyses in each group. Then, DFS was studied for each group according to the six- to eight-month status (remission or not). RESULTS: DFS at 10 years was 75% for the entire cohort and was 89%, 67%, and 82% in groups 1, 2, and 3, respectively (p < 0.0001). Multivariate analysis identified three factors significantly associated with reduced DFS: lymph node (LN) involvement, male sex, and group 2 (>1 cm with ETI). A trend toward a worse prognosis in patients with pT3 N0/Nx PTC >10 mm with ETI was found in comparison with the other pT3 N0/Nx patients. When the six- to eight-month checkup was normal, the DFS at 10 years increased to 98%, 96%, and 91% in groups 1-3, respectively. Furthermore, in this case, initial LN involvement no longer seemed to affect the prognosis in those groups. CONCLUSION: PTC ≤10 mm with ETI and large tumors >4 cm without ETI both have a low-recurrence risk when there are no adverse associated prognostic features such as LN involvement. LN involvement, especially in the lateral compartment (N1b), is a strong prognostic factor of recurrence in pT3 PTC. Delayed risk stratification can be applied in pT3 PTC patients. Those cured at the first checkup, including those with limited LN involvement, have excellent outcomes, which should prompt clinicians to adapt subsequent management accordingly.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Tavarelli M, Sarfati J, Chereau N, et al. Heterogeneous Prognoses for pT3 Papillary Thyroid Carcinomas and Impact of Delayed Risk Stratification. Thyroid. 2017. PMID: 28351220. doi:10.1089/thy.2016.0512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。